TD Asset Management Inc. In the first quarter, ICU Medical, Inc. (NASDAQ: ICUI – Get Rating) rose 8.8%, according to its most recent 13F filing with the Securities and Exchange Commission. The fund held 160,970 shares of the medical device company after selling 15,618 shares during the period. TD Asset Management Inc. owned approximately 0.67% of ICU Medical for $35,838,000 at the end of the last reporting period.
Several other hedge funds and other institutional investors have recently revised their ICUI holdings. Quadrant Capital Group LLC increased its stake in ICU Medical stock by 81.5% during the first quarter. Quadrant Capital Group LLC now owns 118 shares of the medical device company, valued at $26,000, after purchasing an additional 53 shares in the previous quarter. Van Eck Associates Corp increased its stake in ICU Medical by 16.1% during the first quarter. Van Eck Associates Corp. now owns 469 shares of the $104,000 medical-device maker, after buying an additional 65 shares in the previous quarter. Advisor Group Holdings Inc. increased its stake in ICU Medical by 7.5% in the fourth quarter. Advisor Group Holdings Inc. now owns 847 shares of the medical device maker, valued at $202,000, after purchasing an additional 59 shares in the previous quarter. Hightower 6M Holding LLC acquired a new position in ICU Medical stock valued at approximately $218,000 during the first quarter. Finally, Inspire Investing LLC acquired a new position in ICU Medical stock valued at approximately $233,000 during the first quarter. Hedge funds and other institutional investors own 94.93% of the company’s shares.
Analyst upgrades and downgrades
Several equity analysts recently rated the company. KeyCorp lowered its price target on ICU Medical from $230 Tuesday, August. The Street downgraded ICU Medical from a “B-” rating to a “C” rating in a research note on Wednesday, May 11. Finally, StockNews.com downgraded ICU Medical to a “sell” rating from a “hold” rating in a Friday research note.
Medical value display in the intensive care unit
ICU Medical stock opened at $167.11 on Friday. ICU Medical, Inc. 12-month low of $158.60 and 12-month high of $282.00. The company has a current ratio of 2.45, a quick ratio of 1.25 and a debt-to-equity ratio of 0.78. The company’s 50-day simple moving average is $169.60 and its 200-day simple moving average is $197.25. The company has a market cap of $3.99 billion, a price-to-earnings ratio of 397.89 and a beta of 0.55.
ICU Medical (NASDAQ: ICUI – Get Rating) last issued its earnings results on Monday, August 8th. The medical device company reported earnings per share (EPS) of $1.37 for the quarter, not missing the consensus estimate of $1.68 ($0.31). The company’s revenue for the quarter was $561.00 million compared to analysts’ expectation of $569.30 million. ICU Medical had a return on equity of 6.97% and a net margin of 0.31%. The company’s revenue rose 74.4% year over year. In the same quarter last year, the company earned $1.57 per share. The sell-off analysts estimate that ICU Medical, Inc. will post 5.23 EPS for the year to date.
ICU Medical company profile
ICU Medical, Inc., together with its subsidiaries, develops, manufactures and markets medical devices used in infusion therapy and critical care applications worldwide. The Company’s infusion therapy products include Microclave, Microclave Clear and Nanoclave needle-free products; neutron catheter patented device; SwabCap and SwabTip disinfection cap; Tego hemodialysis connector; ClearGuard HD, an antimicrobial protective cap for hemodialysis catheters; and Chemoclave and Chemolock obsolete system transfer devices, and the Dyna Dangerous Drug Compounding System for preparing dangerous drugs.
Want to see what other hedge funds are holding ICUI? ICU Medical, Inc. Visit HoldingsChannel.com for the latest 13F filings and insider trading for (NASDAQ: ICUI – GET RATINGS).
Receive news and reviews for ICU Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ICU Medical and related companies with MarketBeat.com’s FREE daily email newsletter.